This article is more than 5 years old. Information may no longer be current.

VIDEO: Luminate meets primary, secondary endpoints in phase 2b trial

Issue: October 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — At the Ophthalmology Innovation Summit here, Vicken Karageozian, MD, president and chief medical officer of Allegro Ophthalmics, discusses the results of the phase 2b DEL MAR clinical trial of Luminate for treating diabetic macular edema.
In the controlled, double-masked, multicenter, dose-ranging study, Luminate (ALG-1001) met both its primary endpoint for visual acuity and secondary endpoint for reduction in central macular thickness as measured by OCT.